The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Zacks Investment Research on MSN
How a rival's clinical setback sent BBIO stock to a 52-week high
Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage ...
BridgeBio Pharma BBIO is moving from a launch-driven story toward a broader commercial execution test. Attruby has quickly ...
- Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR-CM patients with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025, ...
BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial ...
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...
Shares of BridgeBio (BBIO) are nearing 52-week highs following the fourth quarter results and the commercial update on Attruby which is off to a very strong start in the United States with over 1,000 ...
No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results